23andMe Investor Presentation Deck
Segment Information and Reconciliation of Non-GAAP
Financial Measures
Note: Fiscal year ends March 31.
(unaudited)
(in $K)
Segment Revenue
Consumer & Research Services
Therapeutics
Total Revenue
Segment Adjusted EBITDA
Consumer & Research Services
Therapeutics
Unallocated Corporate
Total Adjusted EBITDA
Reconciliation of Net Loss to Adjusted EBITDA
Net Loss
Adjustments:
Interest (income), net
Other (income) expense, net
Change in fair value of warrant liabilities
Income tax benefit
Depreciation and amortization
Amortization of acquired intangible assets
Stock-based compensation expense
Total Adjusted EBITDA
Three Months Ended June 30,
FY2023
Amount
$64,513
$64,513
($16,997)
(18,465)
(14,253)
($49,715)
($89,532)
(245)
435
(254)
5,104
4,315
30,462
($49,715)
FY2022
Amount
$59,239
$59,239
($505)
(18,303)
(8,467)
($27,275)
($42,026)
(44)
(14)
534
4,638
9,637
($27,275)View entire presentation